Perspective Technologies of Vaccination: Do We Still Need Old Vaccines?

Isaguliants, Maria; Burt, Felicity J.

doi:10.3390/vaccines10060891

Cited by 1 publication

(1 citation statement)

References 29 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These vaccines directly translate in the cytoplasm and support higher expression levels of antigenic components without being integrated into the host genome. The mRNA vaccine against the SARS-CoV-2 virus has recently proven beneficial and changed the perspective toward modern vaccination strategies [ 28 ]. Despite the advances in recombinant DNA technology, these nucleic acid-based recombinant vaccines often suffer various limitations, such as poor stability, low immunogenicity, inefficiency in vaccine delivery, and risks of genomic integration [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

Challenges and Opportunities in the Process Development of Chimeric Vaccines

Chauhan,

Khasa

2023

Vaccines

View full text Add to dashboard Cite

Vaccines are integral to human life to protect them from life-threatening diseases. However, conventional vaccines often suffer limitations like inefficiency, safety concerns, unavailability for non-culturable microbes, and genetic variability among pathogens. Chimeric vaccines combine multiple antigen-encoding genes of similar or different microbial strains to protect against hyper-evolving drug-resistant pathogens. The outbreaks of dreadful diseases have led researchers to develop economical chimeric vaccines that can cater to a large population in a shorter time. The process development begins with computationally aided omics-based approaches to design chimeric vaccines. Furthermore, developing these vaccines requires optimizing upstream and downstream processes for mass production at an industrial scale. Owing to the complex structures and complicated bioprocessing of evolving pathogens, various high-throughput process technologies have come up with added advantages. Recent advancements in high-throughput tools, process analytical technology (PAT), quality-by-design (QbD), design of experiments (DoE), modeling and simulations, single-use technology, and integrated continuous bioprocessing have made scalable production more convenient and economical. The paradigm shift to innovative strategies requires significant attention to deal with major health threats at the global scale. This review outlines the challenges and emerging avenues in the bioprocess development of chimeric vaccines.

show abstract

Section: Introductionmentioning

confidence: 99%